Sort
82,697 grants matching “vaccine development”
Defining targets of protective immunity to vivax malaria using human monoclonal antibodies
$714,622Christopher L King · Case Western Reserve University · R01 · FY2021 · AI
Natural Killer cells and the Immunogenetics of COVID-19
$714,601Paul John Norman · University Of Colorado Denver · R01 · FY2023 · AI
Characterizing Host-Virus Interactions in a New HIV Model Organism
$714,543Sara Sawyer · University Of Colorado · R01 · FY2025 · OD
The Functional Significance of CTL Escape
$714,519David I Watkins · University Of Wisconsin-Madison · R37 · FY2010 · AI
Plant-derived vaccines against hepatitis C Cooperative *
$714,512Charles Joel Arntzen · Arizona State University-Tempe Campus · U19 · FY2008 · AI
Rejuvenation of the T-cell compartment in aging primates
$714,414Louis J. Picker · Oregon Health & Science University · R01 · FY2011 · AI
Modulating antigenic and immunogenic properties of HIV Env by altering signal sequence
$714,413Chitra Upadhyay · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · AI
Establishment of Specific Free Rhesus and Pigtail Macques Colonies
$714,389Michael K Axthelm · Oregon Health & Science University · U24 · FY2013 · OD
Gene Transfer and Somatic Cell Engineering Core
$714,375Isabelle Riviere · Sloan-Kettering Inst Can Research · P01 · FY2009 · CA
The development of a recombinant vaccine against human onchocerciasis
$714,313Sara Lustigman · New York Blood Center · R01 · FY2010 · AI
Non-inferiority trial of a therapeutic vaccine against Chagas disease in naturally-infected rhesus macaques
$714,298Eric Dumonteil · Tulane University Of Louisiana · R01 · FY2024 · AI
Protective role of V2 antibodies induced at mucosal tissues in macaques
$714,266Miroslaw K Gorny · New York University School Of Medicine · R01 · FY2018 · AI
Molecularly Engineered Lectins for Intranasal Prophylaxis and Treatment of Coronaviruses
$714,193David Michael Markovitz · University Of Michigan At Ann Arbor · R01 · FY2024 · AI
Molecularly Engineered Lectins for Intranasal Prophylaxis and Treatment of Coronaviruses
$714,193David Michael Markovitz · University Of Michigan At Ann Arbor · R01 · FY2025 · AI
Project 2: RNA vaccination in early life to induce potent and broad HIV Env-specific antibody responses
$714,185Genevieve Giny Fouda Amou Ou · Weill Medical Coll Of Cornell Univ · P01 · FY2021 · AI
Effectiveness and Safety of Transcatheter Left Atrial Appendage Occlusion vs. Anticoagulation in Older Adults with Atrial Fibrillation and Alzheimer's Disease and Related dementias
$714,181Joshua K Lin · Brigham And Women'S Hospital · R01 · FY2024 · AG
Novel Targets for Vaccine Therapy
$714,123Claudia Palena · Division Of Basic Sciences - Nci · ZIC · FY2017 · CA
Fusion inhibitors that block host-to-host transmission of SARS-CoV-2
$714,110Matteo Porotto · Columbia University Health Sciences · R01 · FY2023 · AI
Multiscale modeling of influenza vaccination strategies for optimal T cell immunity
$714,104Jacob E Kohlmeier · Emory University · U01 · FY2018 · HL
GLP Toxicology Study for Adjuvanted HIV-1 Immunogen Vaccine Candidates
$714,077Deborah Bunin · Sri International · N01 · FY2025 · AI
Live Attenuated SIV-Mediated Protection Against Mucosal SIV Infection
$714,064R. Paul Johnson · Beth Israel Deaconess Medical Center · U19 · FY2012 · AI
Adolescent health behaviors in the time of COVID-19
$713,989Michele Ybarra · Center For Innovative Public Health Research · R01 · FY2024 · HD
Multiscale Computational Microscopy of HIV-1
$713,887Rommie E Amaro · University Of California, San Diego · R01 · FY2023 · AI
Development of dual inhibitors targeting the viral main protease and the host cathepsin L as SARS-CoV-2 antivirals
$713,864Jun Wang · Rutgers Biomedical And Health Sciences · R01 · FY2025 · AI
De Novo Design of Minibinder Antagonists for COVID-19 and Future Pandemics
$713,861David Baker · University Of Washington · R01 · FY2022 · AI